Skip to main content
. 2021 Feb 26;7:38. doi: 10.1038/s41420-021-00421-3

Fig. 6. Targeting SOAT1 synergizes with nystatin in suppressing the viability of colon cancer cells in vivo.

Fig. 6

A SW480 cells were implanted subcutaneously in nude mice, and randomly divided into 4 groups (N = 6). Each group was intraperitoneal injection with control solvent (normal saline, PEG300, and DMSO), avasimibe (15 mg/kg.d), nystatin (4 mg/kg.d) and combined drugs. After 4 weeks, the xenografts were measured and weighed. The bar graphs indicate tumor volume and weight of each group. B Representative pictures of YAP staining in xenograft tumor tissues. The graph indicates the IHC scores of YAP expression. Scale bar: 20 μm. C Mouse models of AOM/DSS-induced colorectal cancer were described in ‘Materials and methods’ section. The mice were randomly divided into 4 groups (N = 5), each group was intraperitoneally injected with control solvent, avasimibe (15 mg/kg.d), nystatin (4 mg/kg.d) and combined drugs during the period of drinking normal water. The graphs showed the average number and tumor area of each group. Statistical methods: one-way ANOVA followed by Tukey post hoc test, *p < 0.05, **p < 0.01, ***p < 0.001, NS indicates no significant difference. D The model of regulation of YAP by cholesterol in colon cancer. LRP6 is released from the cholesterol-rich membranes (lipid rafts) and directly binds to FZD7, resulting in the inactivation of PCP-YAP pathway and classical Wnt pathway when lack of cholesterol. After membrane cholesterol levels increased, LRP6 is transfered to cholesterol-rich area, alleviating the inhibitory effect of LRP6 on PCP-YAP pathway, and activating classical Wnt pathway simultaneously.